More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- CNBC Anchor Takes a Sabbatical
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- NBA D-League On The Rise
- Privately Held Facebook Creates Dual-Class Stock
- On Twitter, Beware False Prophets
- Boeing, Duke Energy Win Smart Grid Stimulus Grants
- Madoff—The Holiday Drink
- Nov. 24: Unusual Volume Leaders
- Citi Mortgage Reveals What Treasury Won't
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- Call Me Crazy: Confessions of a Black Friday Shopper
- US Firms Hit by Payroll Taxes at Exactly the Wrong Time
- Citi Mortgage Reveals Something the US Treasury Won't
- Fed Sanguine About US Recovery, Worried on Jobs
- Amended Berkshire Filing Reveals No 'Secret' Holdings
- In Time for Holidays: More Gloom and Doom on Economy
- Market Pros Reveal Top Black Friday Trades
- Holiday Guide to This Season's Smartphones
- Turkey Day 101: How Well Do You Know Your Bird?
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
I've had to permanently delete reports a few times already because the files are so big. So, I'm gonna stay away from all that here. Instead, I want to highlight what I think is one of the most interesting studies released last night. It's not really a needle-mover (at least, not yet) for the world's biggest drug company, Pfizer [PFE
Loading...
()
] , but it's definitely a good watercooler, talkabout item.
Pfizer markets a new stop-smoking pill Chantix which despite a recent psychiatric side-effect warning looks like it could be a blockbuster-in-the-making. But could it also have an unlikely, older product to offer smokers as well? Researchers at Houston's MD Anderson Cancer Center one of the nation's leading oncology hospitals, think so.
They put out this press release when the embargo lifted on all of the ASCO studies at 9 pm ET last night touting a study that shows Pfizer's painkiller Celebrex may help prevent lung cancer.
Doctors enrolled a couple hundred current and former smokers in the study and gave them two different doses of Celebrex. And especially among the current smokers who got the highest dose of Celebrex they report a decrease in "markers" for lung cancer. What's going on? In simple terms, the experts say there's something called a COX-2 enzyme that lives in tumors and that fuel their growth. Celebrex is a COX-2 inhibitor.
Celebrex is the only COX-2 inhibitor still for sale. Merck [MRK
Loading...
()
] pulled Vioxx and Pfizer pulled Bextra off the market a few years ago because of heart side effects. In fact, this study was stopped for awhile during the COX-2 safety scare, but later given a green light to resume once officials were comfortable Celebrex wouldn't hurt people. Indeed, the researchers report that they've seen no heart side effects in this approximately six-year study.
Dr. Waun Ki Hong is quoted in the press release as saying, "The Celebrex findings are exciting for the entire field of lung cancer chemoprevention." He and his colleagues will present updated data from the study, funded by the National Cancer Institute, at the ASCO meeting at the end of this month.
Celebrex sales took a hit during the Vioxx-Bextra recall fallout, but have been climbing back. Revenue was $2.3 billion last year, up from $2 billion in 2006, but still well below 2004's $3.3 billion (Vioxx was pulled at the end of the third quarter of that year.)
In a down market, PFE shares, as I write this, are back in the "teenager" category again.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes